Biotech / Pharma startups face the longest development timelines (10-15 years from discovery to market) and highest capital requirements (€1-2B for a new drug). But successful drugs generate billions annually with patent protection. The business model is fundamentally different: milestone-based funding, partnerships with big pharma, and regulatory milestones as value inflection points.
Pharma Development Phases:
- Discovery: Target identification, compound screening (2-4 years)
- Preclinical: Animal studies, toxicology (1-2 years)
- Phase I: Safety in healthy volunteers (1 year, 20-80 people)
- Phase II: Efficacy and dosing (1-2 years, 100-300 patients)
- Phase III: Large-scale efficacy (2-4 years, 1,000-5,000 patients)
- Regulatory Review: FDA/EMA review (1-2 years)
- Launch: Commercial launch and Phase IV post-market surveillance
Key Takeaways
- Biotech: 10-15 year timelines, €1B+ total investment.
- Only ~10% of drugs in clinical trials reach market.
- Phase II results = biggest value inflection point.
- Most exits are acquisition by big pharma, not IPO.
Frequently Asked Questions
What percentage of drugs that enter clinical trials eventually reach the market?▼
Answer: 5-10%
Only about 10% of drugs entering Phase I clinical trials ultimately receive approval. This high failure rate drives the need for massive capital and portfolio approaches.
When does a biotech startup become most valuable?▼
Answer: After successful Phase II results
Successful Phase II results (proof of efficacy) are the biggest value inflection point. This is when big pharma acquisition offers typically come.
How do most biotech startups exit?▼
Answer: Acquisition by big pharma after Phase II/III results
Most successful biotechs are acquired by big pharma companies who have the resources for Phase III trials and global commercialization.